|
|
Table 1. Strains of NDV Tested in
Human/Clinical Cancer Studiesa
NDV Strain
|
Strain Type
|
Formulation
|
Suggested Mechanism(s) of
Action
|
Reference
Citation(s)
|
73-T |
Lytic |
Infectious virus |
Cancer cells killed by virus; stimulation of immune system |
[21] |
73-T |
Lytic |
Oncolysate vaccineb |
Stimulation of immune system |
[12,36,39,54,57,59,61-64] |
Ulster |
Nonlytic |
Infected tumor-cell vaccine |
Stimulation of immune system |
[43,44,46-52,65-67] |
MTH-68 |
Lytic |
Infectious virus |
Cancer cells killed by virus; stimulation of immune
system |
[1,7,55,60] |
Italien |
Lytic |
Oncolysate vaccine/infectious virus |
Stimulation of immune system; cancer cells killed by
virus |
[56,58] |
Hickman |
Lytic |
Infectious virus |
Cancer cells killed by virus; stimulation of immune
system |
[73] |
PV701 |
Lytic |
Infectious virus |
Cancer cells killed by virus; stimulation of immune
system |
[53] |
aSee text for more details.
|
bOncolysates are prepared from virus-infected cancer cells; they consist
primarily of cell membrane fragments and contain virus proteins and cancer
cell proteins.
|
References
-
Csatary LK, Moss RW, Beuth J, et al.: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19 (1B): 635-8, 1999 Jan-Feb.
[PUBMED Abstract]
-
Csatary LK, Eckhardt S, Bukosza I, et al.: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17 (6): 619-27, 1993.
[PUBMED Abstract]
-
Batliwalla FM, Bateman BA, Serrano D, et al.: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4 (12): 783-94, 1998.
[PUBMED Abstract]
-
Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18: 863-8, 1965.
-
Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9 (4): 169-71, 1992.
[PUBMED Abstract]
-
Zorn U, Duensing S, Langkopf F, et al.: Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm 12 (3): 157-65, 1997.
[PUBMED Abstract]
-
Liebrich W, Schlag P, Manasterski M, et al.: In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27 (6): 703-10, 1991.
[PUBMED Abstract]
-
Ockert D, Schirrmacher V, Beck N, et al.: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2 (1): 21-8, 1996.
[PUBMED Abstract]
-
Ahlert T, Sauerbrei W, Bastert G, et al.: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15 (4): 1354-66, 1997.
[PUBMED Abstract]
-
Möbus V, Horn S, Stöck M, et al.: Tumor cell vaccination for gynecological tumors. Hybridoma 12 (5): 543-7, 1993.
[PUBMED Abstract]
-
Pecora AL, Rizvi N, Cohen GI, et al.: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20 (9): 2251-66, 2002.
[PUBMED Abstract]
-
Cassel WA, Murray DR, Phillips HS: A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52 (5): 856-60, 1983.
[PUBMED Abstract]
-
Csatary LK: Viruses in the treatment of cancer. Lancet 2 (7728): 825, 1971.
[PUBMED Abstract]
-
Mallmann P: Autologous tumor-cell vaccination and lymphokine-activated tumor-infiltrating lymphocytes (LAK-TIL). Hybridoma 12 (5): 559-66, 1993.
[PUBMED Abstract]
-
Plager C, Bowen JM, Fenoglio C, et al.: Adjuvant immunotherapy of M.D. Anderson Hospital (MDAH) stage III-B malignant melanoma with Newcastle disease virus oncolysate. [Abstract] Proceedings of the American Society of Clinical Oncology 9: A-1091, 281, 1990.
-
Mallmann P, Eis-Hubinger AM, Krebs D: Lymphokine-activated tumor-infiltrating lymphocytes and autologous tumor vaccine in breast and ovarian cancer. Onkologie 15: 490-6, 1992.
-
Anton P, Kirchner H, Jonas U, et al.: Cytokines and tumor vaccination. Cancer Biother Radiopharm 11 (5): 315-8, 1996.
[PUBMED Abstract]
-
Csatary LK, Bakács T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281 (17): 1588-9, 1999.
[PUBMED Abstract]
-
Cassel WA, Murras DR, Torbin AH, et al.: Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 40 (2): 672-9, 1977.
[PUBMED Abstract]
-
Kirchner HH, Anton P, Atzpodien J: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13 (3): 171-3, 1995.
[PUBMED Abstract]
-
Proebstle TM, Staib G, Kaufmann R, et al.: Autologous active specific immunization (ASI) therapy for metastatic melanoma [abstract from Fifth World Conference on Cancers of the Skin]. Melanoma Res 3: A-133, 35, 1993.
-
Pomer S, Thiele R, Staehler G, et al.: [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization] Urologe A 34 (3): 215-20, 1995.
[PUBMED Abstract]
-
Wheelock EF, Dingle JH: Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 271(13): 645-51, 1964.
|
|
|